Compile Data Set for Download or QSAR
Report error Found 31 Enz. Inhib. hit(s) with all data for entry = 10240
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522066(US11155558, Compound mirodenafil)
Affinity DataIC50: 100nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522094(US11155558, Compound 14)
Affinity DataIC50: 100nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522091(US11155558, Compound 5)
Affinity DataIC50: 100nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522095(US11155558, Compound 15)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM14390(SILDENAFIL CITRATE | Sildenafil# | CHEMBL192 | 5-[...)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522093(US11155558, Compound 8)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522092(US11155558, Compound 6)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522090(US11155558, Compound 3q)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522087(US11155558, Compound 3l)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522084(US11155558, Compound 3p | US11155558, Compound 3h)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522080(US11155558, Compound 3d)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522078(US11155558, Compound 2d)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522076(US11155558, Compound 2a)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522077(US11155558, Compound 2b)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522075(US11155558, Compound 1o)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522070(US11155558, Compound 1i)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522074(US11155558, Compound 1n)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522071(US11155558, Compound 1k)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522072(US11155558, Compound 1l)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522073(US11155558, Compound 1m)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522067(US11155558, Compound 1a)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522068(US11155558, Compound 1b)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522069(US11155558, Compound 1d)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522084(US11155558, Compound 3p | US11155558, Compound 3h)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522088(US11155558, Compound 3o)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522086(US11155558, Compound 3k)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522085(US11155558, Compound 3i)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522083(US11155558, Compound 3g)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522082(US11155558, Compound 3f)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522081(US11155558, Compound 3e)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Topadur Pharma

US Patent
LigandPNGBDBM522079(US11155558, Compound 2g)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibition of recombinant human (rh) PDE5A by test compounds is measured in a radiometric assay based on Scintillation Proximity Assay (SPA) tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent